Adverse events · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine led to lower adverse events compared with placebo (Unit of randomisation: transfusion); GRADE not reported.
1 finding from 1 review
Adverse events · Children and adolescents having dental treatment under local anaesthetic (restorative and extraction treatments)
1 finding from 1 review
Withdrawals due to adverse events · women with heavy menstrual bleeding
It is very uncertain whether antifibrinolytics changes withdrawal from treatment because of adverse events compared with ethamsylate (very low certainty).
1 finding from 1 review
One or more adverse events · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Adverse events · people with infective endocarditis due to penicillin‐susceptible Streptococci
It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes adverse events compared with beta‐lactam (ceftriaxone) (very low certainty).
1 finding from 1 review
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Adverse events attributed to KGF were typically oral-related or skin-related; mostly mild to moderate with very few serious events; reporting poor and inconsistent, not appropriate to meta-analyse (SoF comments cell,…
16 studies
GRADE not reported
Adverse events · Adults treated for periodontitis and receiving supportive periodontal therapy (SPT)
1 finding from 1 review
Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID
It is very uncertain whether regimens containing clindamycin plus aminoglycoside changes adverse events: any antibiotic‐related adverse event leading to… compared with regimens containing quinolone (very low certainty).
1 finding from 1 review
RR 0.21 [0.02, 1.72]
Studies not reported
Very low
Withdrawals due to adverse events · people with TTR‐FAP
Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Adverse effects: 1. General ‐ overall number of events · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ general ‐ total general adverse events ( compared with placebo (low certainty).
1 finding from 1 review
Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
It is very uncertain whether four‐food elimination and amino acid formula changes withdrawals due to adverse events at 6 weeks compared with four‐food elimination diet (very low certainty).
1 finding from 1 review
Adverse events: psychological disorders · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ psychiatric disorders ‐ total psychiatric disorders ( compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ nervous system disorders ‐ total nervous system disorders ( · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ nervous system disorders ‐ total nervous system… compared with placebo (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ gastrointestinal disorders ‐ total gastrointestinal… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsr
CoronaVac – Sinovac showed no clear difference in serious adverse eventsr compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsi
WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsk
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found